お知らせ • Oct 16
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
Pharvaris announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have been accepted for e-Poster presentation: Poster: Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study, Speaker: John Anderson, M.D., Format: e-Poster (R102), Date, Time:Oct. 25, 2:00-2:15 p.m. EDT, Location: Monitor 21, Exhibit Hall A. · Poster: Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension, Study Results, Speaker: John Anderson, M.D., Format: e-Poster (R103), Date, Time:Oct. 25, 2:15-2:30 p.m. EDT, Location: Monitor 21, Exhibit Hall A, Poster: Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders, Speaker: Evangelia Pardali, Ph.D., Format: e-Poster (R088), Date, Time:Oct. 25, 2:30-2:45 p.m. EDT, Location: Monitor 20, Exhibit Hall A, Poster: Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated, Disorders, Speaker: Evangelia Pardali, Ph.D., Format: e-Poster (R090), Date, Time:Oct. 25, 3:00-3:15 p.m. EDT, Location: Monitor 20, Exhibit Hall A, · Poster: The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in Humans, Speaker: Juan Bravo, Ph.D., Format: e-Poster (R112), Date, Time:Oct. 25, 4:30-4:45 p.m. EDT, Location: Monitor 21, Exhibit Hall A, Poster: CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary, Angioedema Prophylaxis, Speaker: H. James Wedner, M.D., Format: e-Poster (R100), Date, time:Oct. 25, 5:30-5:45 p.m. EDT, Location: Monitor 20, Exhibit Hall A, Poster: Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life, Speaker: H. James Wedner, M.D., Format: e-Poster (R101), Date, Time:Oct. 25, 5:45-6:00 p.m. EDT, Location: Monitor 20, Exhibit Hall A, Canadian Society of Allergy and Clinical Immunology (CSACI),Banff, Alberta, Canada, November 6-9, 2024. Three, abstracts have been accepted for poster presentation., Poster: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE, Attacks: Results of CHAPTER-1 Phase 2 Trial, Speaker: William H. Yang, M.D., FRCPC, FAAAAI, Format: Poster, Date, Time: Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) andNov. 8, 1:30-2:00, p.m. MST (3:30-4:00 p.m. EST), Poster: Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results, Speaker: William H. Yang, M.D., FRCPC, FAAAAI, Format: Poster, Date, Time: Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) andNov. 8, 1:30-2:00, p.m. MST (3:30-4:00 p.m. EST), Poster: Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study results?, Speaker: Hugo Chapdelaine, M.D., FRCPC, Format: Poster, Date, Time: Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) andNov. 8, 1:30-2:00, p.m. MST (3:30-4:00 p.m. EST), Japanese Society of Allergology (JSA),Kyoto, Japan, October 18-20, 2024. One abstract has been accepted for oral presentation. Presentation: Efficacy and safety of oral deucrictibant IR capsule in HAE: RAPIDe-3 phase 3 trial design Speaker: Prof. Michihiro Hide, M.D., Ph.D., Format: Oral Presentation, Date, Time: Sunday, Oct. 20, 13:30-14:45 JST (12:30 -1:45 a.m. EDT).